

From: White, Brandon (Perkins Coie)
To: [Trials](#)
Cc: T.Blinka@cooley.com; J.Graves@cooley.com; E.Scordino@cooley.com; Stephen.Hash@bakerbotts.com; Margaret.Sampson@bakerbotts.com; Jeff.Gritton@bakerbotts.com; apollack@buddlarner.com; dshelhoff@buddlarner.com; ssender@buddlarner.com; lweinstein@buddlarner.com; [Greb, Emily J. \(Perkins Coie\)](mailto:Greb,Emily.J.(PerkinsCoie)@perkinscoie.com); EsoNaproxen@perkinscoie.com; [Bloodworth, Shannon \(Perkins Coie\)](#)
Subject: IPR2018-00272 & IPR2017-01995: Notice of Bankruptcy and Request for Teleconference
Date: Wednesday, August 29, 2018 11:19:08 AM

Dear Board,

On August 28, 2018, one of the Patent Owners, Pozen Inc., filed Suggestions of Bankruptcy in IPR2018-00272 and IPR2017-01995. Paper Nos. 12 and 50, respectively. Patent Owner asserts that these filings effect a stay of each of these IPRs by statute. Petitioners request a conference call as soon as possible to address the impact of these filings on the procedural schedule in these cases, if any, and any orders or briefing that may be necessary in view of these filings. Petitioners note that a deposition is scheduled for this coming Friday, August 31 in IPR2017-01995, and Petitioners' Reply brief deadline is Friday, September 7, 2018.

Respectfully submitted,

Brandon White
Counsel for Petitioner Mylan Pharmaceuticals Inc.

Brandon White | Perkins Coie LLP

PARTNER
700 Thirteenth Street, N.W. Suite 600
Washington, DC 20005-3960
D. +1.202.654.6206
F. +1.202.654.9681
E. BMWhite@perkinscoie.com

NOTICE: This communication may contain privileged or other confidential information. If you have received it in error, please advise the sender by reply email and immediately delete the message and any attachments without copying or disclosing the contents. Thank you.